Grove Bank & Trust’s BioLife Solutions BLFS Stock Holding History

Grove Bank & Trust’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-46	Closed	-$635	–	600
2023 Q3	$635	Buy	+46	New	+$725	﹤0.01%	721

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Grove Bank & Trust's BLFS Position: Q4 2023 in Review

Grove Bank & Trust sold out of BioLife Solutions (BLFS) in Q4 2023, closing a stake of 46 shares — an estimated $635 sold.

Grove Bank & Trust first reported a position in BLFS in Q3 2023 and held it in 1 quarter. The position peaked at $635 in Q3 2023. 140 funds tracked by Wall St. Rank hold BLFS as of Q4 2023.

Grove Bank & Trust reported no remaining BioLife Solutions position as of Q4 2023 after selling out during the quarter.
Grove Bank & Trust sold 46 BioLife Solutions shares in Q4 2023, an estimated $635.
Grove Bank & Trust first reported a position in BioLife Solutions in Q3 2023 and held it in 1 quarter.
Grove Bank & Trust's BioLife Solutions position peaked at $635 in Q3 2023.
140 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.